{"favorite_id": 10082, "calc_type": "", "dosing": false, "full_title_en": "WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome", "short_title_en": "WPSS", "medium_description_en": "Evaluates prognosis of patients with myelodysplastic syndrome (MDS).", "short_description_en": "MDS survival.", "before_use": "", "instructions_en": "", "purpose_en": ["Prognosis"], "disease_en": ["Cancer", "Hematologic Malignancy"], "specialty_en": ["Hematology and Oncology"], "chief_complaint_en": ["Bleeding"], "system_en": ["Hematologic", "Oncologic"], "search_abbreviation_en": ["MDS", "WHO MDS scoring", "WPSS", "Myelodysplastic Syndrome"], "slug": "wpss-classification-based-prognostic-scoring-system-myelodysplastic-syndrome", "seo": {"meta_description_en": "The WPSS (WHO classification-based Prognostic Scoring System) for Myelodysplastic Syndrome evaluates the prognosis of patients with MDS.", "keywords_en": "WPSS, WHO, prognostic scoring, Myelodysplastic Syndrome, MDS"}, "content": {"how_to_use": {"use_case_en": "<p>Do you use the WPSS for Myelodysplastic Syndrome and want to contribute your expertise? <a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a> our contributor team!</p>", "pearls_pitfalls_en": "", "why_use_en": ""}, "next_steps": {"advice_en": "<p>Do you use the WPSS for Myelodysplastic Syndrome and want to contribute your expertise? <a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a> our contributor team!</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\">Addition of the selected points:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Prognostic variable</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>0 points</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>1 point</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>2 points</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>3 points </strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">WHO category</p>\n</td>\n<td>\n<p dir=\"ltr\">Refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), or myelodysplastic syndrome with isolated del (5q)</p>\n</td>\n<td>\n<p dir=\"ltr\">Refractory cytopenia with multilineage dysplasia (RCMD), or refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)</p>\n</td>\n<td>\n<p dir=\"ltr\">Refractory anemia with excess of blasts, 2-4% blasts in peripheral blood (RAEB-1)</p>\n</td>\n<td>\n<p dir=\"ltr\">Refractory anemia with excess of blasts,&nbsp;5-19% blasts in peripheral blood (RAEB-2)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Karyotype*</p>\n</td>\n<td>\n<p dir=\"ltr\">Good</p>\n</td>\n<td>\n<p dir=\"ltr\">Intermediate</p>\n</td>\n<td>\n<p dir=\"ltr\">Poor</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Transfusion requirement**</p>\n</td>\n<td>\n<p dir=\"ltr\">None</p>\n</td>\n<td>\n<p dir=\"ltr\">Regular</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>\u0001*Karyotype is defined as follows: good = normal, &ndash;Y, del(5q), del(20q); poor = complex (\u0001&ge;3 abnormalities), chromosome 7 anomalies; and intermediate = all other abnormalities.</p>\n<p>**Transfusion requirement is defined as having at least one RBC transfusion every 8 weeks over a period of 4 months.</p>\n</div>", "more_info_en": "<p dir=\"ltr\">Interpretation:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"60\" /><col width=\"107\" /><col width=\"115\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>WPSS Score</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Risk group</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Median survival</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n<td>\n<p dir=\"ltr\">Very low</p>\n</td>\n<td>\n<p dir=\"ltr\">141 months</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n<td>\n<p dir=\"ltr\">Low</p>\n</td>\n<td>\n<p dir=\"ltr\">66&nbsp;months</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">2</p>\n</td>\n<td>\n<p dir=\"ltr\">Intermediate</p>\n</td>\n<td>\n<p dir=\"ltr\">48 months</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">3-4</p>\n</td>\n<td>\n<p dir=\"ltr\">High</p>\n</td>\n<td>\n<p dir=\"ltr\">26 months</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">5-6</p>\n</td>\n<td>\n<p dir=\"ltr\">Very high</p>\n</td>\n<td>\n<p dir=\"ltr\">9&nbsp;months</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "http://www.bloodjournal.org/content/106/11/788?sso-checked=true ", "text": "Malcovati L, et al. A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes. Blood. 2005; 106(11)."}], "Other References": [{"href": "", "text": ""}], "Validation": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/17687155", "text": "Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-10."}, {"href": "https://www.ncbi.nlm.nih.gov/pubmed/25721895 ", "text": "Della porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29(7):1502-13."}, {"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100722/ ", "text": "Bekta\u015f \u00d6, \u00dcner A, Elia\u00e7\u0131k E, et al. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems. Turk J Haematol. 2016;33(2):119-26."}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": []}, "reviewer": {"expert_name": []}, "creator": [{"name": "Dr. Luca Malcovati", "creator_info": {"deceased": null, "about_en": "<p>Luca Malcovati, MD, is a hematologist at the IRCCS Policlinico San Matteo Foundation in Pavia, Italy. He is also an associate professor of hematology in the department of molecular medicine at University of Pavia Medical School. Dr. Malcovati\u2019s research interests include myeloid neoplasms, the prognosis of myelodysplastic syndrome, and providing evidence-based guidelines.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-luca-malcovati.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Malcovati+L%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "WHO category", "name": "who", "options": [{"label": "Refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), or myelodysplastic syndrome with isolated del (5q)", "value": 0}, {"label": "Refractory cytopenia with multilineage dysplasia (RCMD), or refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)", "value": 1}, {"label": "Refractory anemia with excess of blasts, 2-4% blasts in peripheral blood (RAEB-1)", "value": 2}, {"label": "Refractory anemia with excess of blasts, 5-19% blasts in peripheral blood (RAEB-2)", "value": 3}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "radio", "label_en": "Karyotype", "name": "karyotype", "options": [{"label": "Good", "value": 0}, {"label": "Intermediate", "value": 1}, {"label": "Poor", "value": 2}], "conditionality": "", "show_points": true, "default": 0, "tips_en": "Defined as follows: good = normal, \u2013Y, del(5q), del(20q); poor = complex (\u0001\u22653 abnormalities), chromosome 7 anomalies; and intermediate = all other abnormalities", "optional": false}, {"type": "radio", "label_en": "Transfusion requirement", "name": "transfusion", "options": [{"label": "None", "value": 0}, {"label": "Regular", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "tips_en": "Defined as having at least one RBC transfusion every 8 weeks over a period of 4 months", "optional": false}], "md5": "f8863267895a11d0e93fb553f66a1ab0", "related_calcs": [{"calcId": 3981, "short_title_en": "IPSS-R", "slug": "revised-international-prognostic-scoring-system-ipss-r-myelodysplastic-syndrome-mds"}, {"calcId": 10041, "short_title_en": "Cytokine Release Syndrome (CRS) Grading", "slug": "cytokine-release-syndrome-crs-grading"}, {"calcId": 3170, "short_title_en": "ECOG Performance Status", "slug": "eastern-cooperative-oncology-group-ecog-performance-status"}]}